Register for our free email digests:
Latest From Dare Bioscience Inc.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
BioLineRx buys Agalimmune and its alpha Gal candidate for melanoma and possibly other oncology indications. Japan's Ono signs an R&D agreement with Switzerland's Numab, while Boston biotechs Vedantra and Neon will collaborate on potential cancer vaccines.
- Therapeutic Areas
- Pacific Rim
- Company Type
- Top Japanese Pharma
- Parent & Subsidiaries
- Teijin Ltd.
- Senior Management
- Jun Suzuki, Pres. & CEO
- Contact Info
Phone: (81) 3 3506 4529
2-1, Kasumigaseki 3-chome
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.